Funding Ophthalmic Innovation
Angela MacFarlane, President & CEO for ForSight Labs and Emmett Cunningham, Partner for Clarus Ventures co-moderate a segment on funding opportunities for innovative products and procedures in the Ophthalmic space, at the 2nd Annual Ophthalmology Innovation Summit on April 18, 2013. Lending their expert insights on the funding process are panelists Calvin W. Roberts, MD, EVP, Chief Medical Officer for Bausch + Lomb, Renee Ryan, Vice President of Venture Investments for Johnson & Johnson Development Corp., Charles Warden, Managing Director for Versant Ventures, Eve Higginbotham SM, MD, Co-Founder and Director for ROI Squared and Professor of Ophthalmology at Emory University, and Lukas Scheibler, VP of Clinical Trial Management for Alcon’s Novartis’ Eye Division.
Emmett T. Cunningham Jr., MD, PhD, MPH
Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham was the SVP, Medical Strategy at Eyetech Pharmaceuticals.
K. Angela Macfarlane
Ms. Macfarlane joined ForSight Labs as President and CEO in March 2007. Over the past nine years, ForSight has started six ForSight VISION companies, that have collectively raised over $130M in capital, and are focused on breakthrough therapies for ophthalmology, including glaucoma, corneal and cataract surgery and treatment of anterior and posterior segment ocular disorders.
Calvin W. Roberts, MD
Calvin W. Roberts, MD, is Executive Vice President and the Chief Medical Officer at Bausch + Lomb. A specialist in cataract and refractive surgery, Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens.
Charles Warden has been an active medical device venture investor since 1992. Charles works closely with entrepreneurial device companies from inception along the path to success.